JNJ NYSE
Johnson & Johnson
1W: -5.6%
1M: -6.9%
3M: -1.2%
YTD: +24.2%
1Y: +38.5%
3Y: +74.7%
5Y: +76.3%
$256.03
-2.63 (-1.02%)
Weekly Expected Move ±2.0%
$246
$251
$256
$261
$266
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
16 relationships6
As Filer
counterparties named
10
As Counterparty
mentioned by others
2
Rel. Types
2021-10-04
Earliest Filing
2023-12-21
Latest Filing
target: 3
partner: 3
Counterparties (Filed by JNJ)
6 relationshipsCompanies named in JNJ's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kenvue Inc. | KVUE | target | Target of Johnson & Johnson's split-off exchange offer. | 2023-08-25 | View |
| Kenvue Inc. | KVUE | partner | Wholly owned subsidiary spun off from Johnson & Johnson via IPO and Separation Agreement | 2023-05-08 | View |
| Johnson & Johnson Consumer Inc. | JNJ | partner | Counterparty to Trademark Phase-Out License Agreement | 2023-05-08 | View |
| ABIOMED, Inc. | ABMD | target | Target company acquired by Johnson & Johnson via merger | 2022-12-22 | View |
| American Stock Transfer & Trust Company, LLC | AIG | partner | Counterparty to the Contingent Value Rights Agreement | 2022-12-22 | View |
| ABIOMED, Inc. | ABMD | target | Target company in the merger agreement to be acquired by Johnson & Johnson. | 2022-11-01 | View |
Mentioned As Counterparty
10 mentionsOther companies that named JNJ in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| MGTX MeiraGTx Holdings plc | investor | Investment arm of Johnson & Johnson that owns more than 10% of MeiraGTx Holdings plc. | 2023-12-21 | View |
| IART INTEGRA LIFESCIENCES HOLDINGS CORP | partner | Parent company of Seller (Ethicon, Inc.) | 2023-12-13 | View |
| VNDA Vanda Pharmaceuticals Inc. | partner | Parent company of Actelion Pharmaceuticals Ltd., the seller in the asset purchase agreement. | 2023-12-07 | View |
| RNTX AILERON THERAPEUTICS INC | partner | Company that acquired Actelion Pharmaceuticals Ltd. | 2023-10-31 | View |
| KVUE Kenvue Inc. | partner | Parent company that spun off the Consumer Health Business into Kenvue Inc. via IPO and Separation Agreement. | 2023-05-08 | View |
| MGTX MeiraGTx Holdings plc | partner | Parent company of the Investor and party to a prior Collaboration, Option and License Agreement | 2022-11-10 | View |
| MIRM Mirum Pharmaceuticals, Inc. | partner | Parent company of Janssen Biotech, Inc., the buyer of the PRV. | 2021-12-22 | View |
| DYAI DYADIC INTERNATIONAL INC | partner | Parent company of Janssen Biotech, Inc., a party to the Research, License, and Collaboration Agreement. | 2021-12-17 | View |
| MIRM Mirum Pharmaceuticals, Inc. | partner | Parent company of Janssen Biotech, Inc. | 2021-11-19 | View |
| XNCR Xencor Inc | investor | Purchased $25 million of newly issued Xencor common stock | 2021-10-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Officer/Director Change; Exhibits | View | |
| 2026-07-29 | Regulation FD; Exhibits | View | |
| 2026-07-28 | Regulation FD; Exhibits | View | |
| 2026-07-15 | Earnings Release; Exhibits | View | |
| 2026-04-28 | Shareholder Vote; Exhibits | View | |
| 2026-04-14 | Earnings Release; Other Events; Exhibits | View | |
| 2026-01-21 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-04-30 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-04-15 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-04-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-02-26 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-22 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-22 | Financial Statements and Exhibits | View | |
| 2024-10-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR